Iga Nephropathy Epidemiology Forecast

DelveInsight’s ‘IgA Nephropathy (IgAN)- Epidemiology Forecast- 2032’ report delivers an in-depth understanding of IgA Nephropathy (IgAN) historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), Japan, and China.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
  • China

Study Period: 2019-2032

IgA Nephropathy (IgAN) Disease Understanding

IgAN is an autoimmune disease that attacks the kidneys and affects blood filtration in the small blood vessels of the kidneys. IgAN occurs when an abnormal protein damages the filtering unit (glomerulus) inside the kidneys.

IgA Nephropathy (IgAN) Epidemiology

IgAN epidemiology report provides insights about the historical and incident patient pool, along with the forecasted trend for all eight major countries. It helps to identify the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The report also provides the diagnosed patient pool, trends, and assumptions.

 

Key Findings

The total prevalent cases of IgAN patients in the 7MM + China are increasing during the study period, i.e., 2019- 2032.

 

The disease epidemiology covered in the report provides historical as well as forecasted IgAN epidemiology segmented as the total prevalent cases, gender-specific cases, and age-specific cases of IgAN. The report includes the prevalent cases of IgAN in the eight major markets covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China from 2019 to 2032.

Country-wise IgA Nephropathy (IgAN) Epidemiology

The epidemiology segment also provides IgAN epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.

  • The prevalent cases of IgAN associated in 7MM + China were approximately 1.7 million in 2021.
  • As per Delveinsight’s estimates, China has the largest prevalent population of IgAN.
  • Among the EU5 countries, Germany had the highest prevalent cases of IgAN, followed by France. On the other hand, Spain had the lowest prevalent cases (~20,000 cases in 2021).

Scope of the Report

  • IgAN report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
  • Epidemiology Report and Model provide an overview of IgAN risk factors and global trends in the eight major markets covering the US, EU5 (France, Germany, Italy, Spain, UK), Japan, and China).
  • The report provides insight into historical and forecasted IgAN patient pool in eight major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China.
  • The report helps to recognize the growth opportunities in the 7MM + China concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of IgAN.
  • The report provides the segmentation of the IgAN epidemiology by the prevalent cases of IgAN in 7MM + China.
  • The report provides the epidemiology segmentation by gender-specific and age-specific cases of IgAN in 7MM + China.

Report Highlights

  • 11-year Forecast of IgAN epidemiology
  • 7MM + China Coverage
  • Prevalent Cases of IgAN
  • Gender-specific cases of IgAN
  • Age-specific Cases of IgAN

KOL Views

We interview KOLs, and SMEs’ opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What are the major factors that will drive the change in the patient population in IgAN during the forecast period (2019-2032)?
  • What are the key findings of the IgAN epidemiology across 7MM + China, and which country will have the highest number of patients during the forecast period (2019-2032)?
  • What would be the total number of IgAN patients across the 7MM + China during the forecast period (2019-2032)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow in 7MM + China during the forecast period (2019-2032)?
  • What are the disease risks, burden, and unmet needs of IgAN market?
  • What are the current treatment patterns for IgAN?

Reasons to buy

IgAN epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global IgAN market.
  • Quantify patient populations in the global IgAN market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for IgAN therapeutics in each market covered.
  • Understand the magnitude of the IgAN population by its prevalence.
  • Understand the magnitude of the IgAN population by its gender-specific cases.
  • Understand the magnitude of the IgAN population by its age-specific cases.
  • IgAN epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • IgAN epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources.

Key Assessments

  • Patient segmentation
  • Disease risk and burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. IgA Nephropathy Market Overview at a Glance

3.1. Market Share (%) Distribution of IgA Nephropathy in 2019

3.2. Market Share (%) Distribution of IgA Nephropathy in 2032

4. Executive Summary of IgA Nephropathy

5. Disease Background and Overview

5.1. Introduction

5.2. Clinical Manifestations

5.3. Risk Factors

5.4. Pathogenesis

5.5. Classification

5.6. Recurrent IgA Nephropathy

5.7. Biomarkers

5.8. Diagnosis

5.8.1. Differential Diagnosis

5.9. Treatment and Management

5.9.1. Treatment Guidelines

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM + China Total Prevalent Population of IgA Nephropathy

6.3. Assumptions and Rationale

6.4. The United States

6.4.1. Total Prevalent Cases of IgA Nephropathy in the United States

6.4.2. Gender-Specific Cases of IgA Nephropathy in the United States

6.4.3. Age-Specific Cases of IgA Nephropathy in the United States

6.5. EU-5

6.5.1. Total Prevalent Cases of IgA Nephropathy in EU-5

6.5.3. Gender-Specific Cases of IgA Nephropathy in EU-5

6.5.4. Age-Specific Cases of IgA Nephropathy in EU-5

6.6. Japan

6.6.1. Total Prevalent Cases of IgA Nephropathy in Japan

6.6.2. Gender-Specific Cases of IgA Nephropathy in Japan

6.6.3. Age-Specific Cases of IgA Nephropathy in Japan

6.7. China

6.7.1. Total Prevalent Cases of IgA Nephropathy in China

6.7.2. Gender-Specific Cases of IgA Nephropathy in China

6.7.3. Age-Specific Cases of IgA Nephropathy in China

7. Patient Journey

8. KOL Views

9. Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Table

Table 1: Summary of IgA Nephropathy, Market, Epidemiology, and Key Events (2019–2032)

Table 2: Oxford Classification of IgAN

Table 3: Classification of IgAN

Table 4: Treatment of IgA Nephropathy

Table 5: Total Prevalent Population of IgA Nephropathy in 7MM + China (2019–2032)

Table 6: Total Prevalent Cases of IgA Nephropathy in the United States (2019–2032)

Table 7: Gender-Specific Cases of IgA Nephropathy in the United States (2019–2032)

Table 8: Age-Specific Cases of IgA Nephropathy in the United States (2019–2032)

Table 9: Total Prevalent Cases of IgA Nephropathy in EU5 (2019–2032)

Table 10: Gender-Specific Cases of IgA Nephropathy in EU-5 (2019–2032)

Table 11: Age-Specific Cases of IgA Nephropathy in EU-5 (2019–2032)

Table 12: Total Prevalent Cases of IgA Nephropathy in Japan (2019–2032)

Table 13: Gender-Specific Cases of IgA Nephropathy in Japan (2019–2032)

Table 14: Age-Specific Cases of IgA Nephropathy in Japan (2019–2032)

Table 15: Total Prevalent Cases of IgA Nephropathy in China (2019–2032)

Table 16: Gender-Specific Cases of IgA Nephropathy in China (2019–2032)

Table 17: Age-Specific Cases of IgA Nephropathy in China (2019–2032)

List of Figures

Figure 1: Clinical Manifestations in IgA Nephropathy

Figure 2: Risk factors involved in IgA Nephropathy

Figure 3: Interactions of major elements of pathogenesis of IgA Nephropathy

Figure 4: Mechanisms involved in the pathogenesis of IgA Nephropathy

Figure 5: Schematic representation of IgAN recurrence in the graft and potential site of drug intervention

Figure 6: Algorithm for the initial assessment and management of the patient with IgAN

Figure 7: Differential Diagnosis of IgA Nephropathy

Figure 8: Algorithm for the treatment of IgA Nephropathy

Figure 9: Management of the patient with IgAN at high risk for progression after maximal supportive care

Figure 10: Management of IgAN: With a focus on renal dysfunction prevention

Figure 11: Total Prevalent Population of IgA Nephropathy in the 7MM + China (2019–2032)

Figure 12: Total Prevalent Cases of IgA Nephropathy in the US (2019–2032)

Figure 13: Gender-Specific Cases of IgA Nephropathy in the United States (2019–2032)

Figure 14: Age-Specific Cases of IgA Nephropathy in the United States (2019–2032)

Figure 15: Total Prevalent Cases of IgA Nephropathy in EU5 (2019–2032)

Figure 16: Gender-Specific Cases of IgA Nephropathy in EU-5 (2019–2032)

Figure 17: Age-Specific Cases of IgA Nephropathy in EU-5 (2019–2032)

Figure 18: Total Prevalent Cases of IgA Nephropathy in Japan (2019–2032)

Figure 19: Gender-Specific Cases of IgA Nephropathy in Japan (2019–2032)

Figure 20: Age-Specific Cases of IgA Nephropathy in Japan (2019–2032)

Figure 21: Total Prevalent Cases of IgA Nephropathy in China (2019–2032)

Figure 22: Gender-Specific Cases of IgA Nephropathy in China (2019–2032)

Figure 23: Age-Specific Cases of IgA Nephropathy in China (2019–2032)

Forward to Friend

Need A Quote